Tarperprumig
Sickle Cell Disease (SCD)
Alexion Pharmaceuticals, Inc.monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
134 Active assets in the Sickle Cell Disease (SCD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Glutamine Ain Shams University | Phase 4 | BBB |
Hydroxyurea St. Jude Children's Research Hospital | Phase 4 | BB |
Crizanlizumab Novartis Pharmaceuticals | Phase 4 | BB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 4 | BB |
MAGNESIUM METALLICUM Medical College of Wisconsin | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →